MD Anderson and Ipsen advance new therapy with potential benefit for underserved patients with lung and ovarian cancers

(University of Texas M. D. Anderson Cancer Center) MD Anderson and Ipsen have advanced a new targeted therapy into clinical trials for certain patients with lung and ovarian cancers. Details are being presented at the AACR Annual Meeting.